METHODS	In this multicentre , open-label , phase 2 study , treatment-naive women with HER2-positive breast cancer were randomly assigned ( 1:1:1:1 ) centrally and stratified by operable , locally advanced , and inflammatory breast cancer , and by hormone receptor expression to receive four neoadjuvant cycles of : trastuzumab ( 8 mg/kg loading dose , followed by 6 mg/kg every 3 weeks ) plus docetaxel ( 75 mg/m ( 2 ) , escalating , if tolerated , to 100 mg/m ( 2 ) every 3 weeks ; group A ) or pertuzumab ( loading dose 840 mg , followed by 420 mg every 3 weeks ) and trastuzumab plus docetaxel ( group B ) or pertuzumab and trastuzumab ( group C ) or pertuzumab plus docetaxel ( group D ) .\